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Mucous membrane pemphigoid (MMP) is an autoimmune bullous disease that primarily affects mucous membranes
leading to a scarring phenotype. MMP patients produce auto-antibodies (auto-ab) that preferentially recognize two
components of the dermoepidermal basement membrane zone (BMZ): bullous pemphigoid (BP)180 and laminin 5
(LN5). Since detection of disease-specific auto-ab may be critical for diagnosis of MMP, we developed an ELISA
with afﬁnity-puriﬁed native human LN5. A total of 24 MMP, 72 BP, and 51 control sera were analyzed for LN5-
specific auto-ab: 18/24 (75.0%) MMP and 29/72 (40.3%) BP sera were LN5 reactive. Sensitivity and speciﬁcity of the
LN5 ELISA for MMP were 75% and 84.3%, respectively, and 40.3% and 88.2% for BP, respectively. The LN5 ELISA
was more sensitive than a dot blot assay with native LN5, which detected LN5-reactive IgG in 14/24 (58.3%) MMP
and 16/72 (22.2%) BP sera. In MMP, but not BP, levels of LN5-reactive IgG correlated with disease severity. Fur-
thermore, IgG reactivity to LN5 of the MMP and BP sera was not significantly associated with IgG reactivity against
other autoantigens of the BMZ, such as BP180 or BP230. Thus, the established LN5 ELISA holds great promise as a
novel diagnostic and prognostic parameter for MMP.
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Mucous membrane pemphigoid (MMP, formerly cicatricial
pemphigoid) is a chronic autoimmune bullous disease that
mainly affects mucous membranes, such as the conjunc-
tivae, oral, and genital mucosa, as well as the perianal re-
gion, leading to scarring of the affected tissue (Bedane et al,
1997; Murakami et al, 1998). Cutaneous involvement is seen
in approximately 20% of the patients and usually affects the
head, neck, and upper trunk. Morbidity because of MMP
may be high, depending on the affected regions. Ocular
involvement bears the risk of symblepharon and an-
kyloblepharon, causing visual impairment or blindness and
laryngeal stenosis may require tracheostomy. The frequen-
cy of laryngeal involvement in MMP is 8%–9% (Anhalt and
Diaz, 1989; Ahmed et al, 1991; Nousari et al, 1999). More-
over, MMP has also been associated with internal malig-
nancies (Egan and Yancey, 2000; Egan et al, 2001). Because
of the risk of these severe complications, early recognition
and aggressive treatment of MMP is essential.
Patients with MMP exhibit IgG and/or IgA auto-antibod-
ies (ab) directed against heterogeneous components of the
dermoepidermal basement membrane zone (BMZ) includ-
ing bullous pemphigoid (BP)180, BP230 (Caproni et al,
2003), the 97/120 kDa LABD antigen, laminin 5 (LN5), LN6
(Domloge-Hultsch et al, 1992; Kirtschig et al, 1995; Ghohes-
tani et al, 1996b; Chan et al, 1997; Bhol et al, 2000), and the
integrin b4 subunit (Tyagi et al, 1996).
Among the various autoantigens of MMP, LN5 and
BP180 are presumably recognized by the majority of the
MMP sera. BP180 is a hemidesmosomal transmembrane
type II protein with a large extracellular portion consisting of
15 interrupted collagenous subdomains located between
a non-collagenous membrane-adjacent domain termed
NC16A and a COOH-terminal domain termed NC1 region
(Giudice et al, 1991; Hopkinson et al, 1992). It serves as a
cell surface receptor (Giudice et al, 1992; Hopkinson et al,
1992), and plays an important role in the maintenance of
epidermal–stromal adhesion (Borradori and Sonnenberg,
1999). Potential ligands of BP180 are a6b4 integrin and LN5,
which have both been identified as autoantigens of MMP
(Hopkinson et al, 1995; Borradori and Sonnenberg, 1999;
Sonnenberg et al, 1999). Mutations within the BP180 gene
(COL17A1) are the cause of a clinical variant of non-Herlitz
junctional epidermolysis bullosa, a congenital disorder char-
acterized by skin fragility and blistering (McGrath et al,
1995). In a passive transfer model, rabbit ab raised against
Abbreviations: ab, antibody; BMZ, basement membrane zone; BP,
bullous pemphigoid; CI, confidence interval; FN, fibronectin; IIF,
indirect immunofluorescence; LN5, laminin 5; MMP, mucous mem-
brane pemphigoid; OD, optical density; PBS, phosphate-buffered
saline; ROC, receiver operating characteristic; RT, room temper-
ature; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel
electrophoresis; SSS, saline split skin; TBS, tris-buffered saline
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the murine homologue of the human NC16A domain of
BP180 were able to induce subepidermal blister formation,
reproducing all key features of BP (Liu et al, 1993). Further-
more, it has been shown that the serum levels of IgG auto-
ab directed against the extracellular domain of BP180 are
related to the severity of BP (Dopp et al, 2000; Hofmann
et al, 2002; Thoma-Uszynski et al, 2004). It is noteworthy
that IgG auto-ab against the COOH-terminal region of the
BP180 ectodomain seem to be associated with the char-
acteristic features of MMP (Nakatani et al, 1998; Lazarova
et al, 2000).
LN5 is a multifunctional glycoprotein of the BMZ that
plays an important role in the initiation and maintenance of
epithelial cell anchorage to the underlying connective tis-
sue. LN5, originally termed nicein (Verrando et al, 1987),
kalinin (from greek walinoB¼ thong or bridle) (Rousselle
et al, 1991; Burgeson et al, 1994), and epiligrin (Carter et al,
1991; Domloge-Hultsch et al, 1992) has been identified as a
heterotrimeric glycoprotein consisting of a3, b3, and g2
subunits that are covalently linked by disulfide bonds. LN5
is produced both by epithelial and mesenchymal cells and is
abundantly expressed in the skin, trachea, esophagus, cor-
nea, amnion, and intestinal smooth muscle (Rousselle et al,
1991), all of which possess hemidesmosomes. It binds to
a3b1 and a6b4 integrins, with the latter being crucial for
hemidesmosome assembly. LN5 is initially synthesized in a
cell-associated form estimated at 460 kDa. The cellular
form contains non-identical subunits of 200–165, 140, 155–
105–80 kDa linked by interchain disulfide bonds (Mar-
inkovich et al, 1992; Jones et al, 1998). Gene defects of the
a3b3g2 chains are the cause of Herlitz and non-Herlitz
junctional epidermolysis bullosa (Pulkkinen et al, 1994,
1995; Vailly et al, 1995). The passive transfer of LN5-reactive
IgG from sera of patients with MMP into neonatal mice re-
produces the pathology with a subepidermal loss of adhe-
sion and the appearance of tense blisters (Lazarova et al,
1996). All three chains of LN5 have been shown to be rec-
ognized by LN5-reactive MMP sera and recent studies uti-
lizing bacteria-derived recombinant proteins suggested that
most MMP sera recognize the G domain of the a3 subunit
(Hisamatsu et al, 2003).
The aim of this study was to develop a highly sensitive
and specific ELISA for the detection of LN5-reactive IgG in a
cohort of MMP and BP sera including a control group. There
is a need to develop new diagnostic tools to identify pa-
tients with MMP with IgG auto-ab against LN5 to prevent
long-term complications of the disease, which is associated
with a late onset of immunosuppressive therapy. Our data
demonstrate that IgG auto-ab against LN5 are not only
present in the majority of MMP sera but also, at lower levels,
in a substantial number of BP sera. Moreover, the IgG titers
against LN5 seem to reflect disease activity and may thus
provide a critical prognostic marker for MMP.
Results
Characterization of the patients’ sera by indirect
immunoﬂuorescence (IIF) Sera from patients with the
clinical diagnosis of MMP or BP were subjected to IIF anal-
ysis utilizing saline-split skin (SSS). Among the MMP sera,
8/24 (33.3%) showed a dermal, 2/24 (8.3%) an epidermal
pattern, and 1/24 (4.2%) a combined epidermal/dermal
pattern whereas 13/24 sera (54.1%) were negative. In con-
trast, the majority, i.e. 58/72 (80.5%) of the BP sera, showed
IgG reactivity with the epidermal side of the SSS whereas 4/
72 (5.5%) reacted with the dermal side of SSS and 2/72 BP
sera showed a combined SSS staining pattern. A total of 8/
72 (11.1%) BP sera were negative by SSS analysis.
Afﬁnity-puriﬁed LN5 is recognized by ab directed
against the LN a3, b3, and c2 chains The quality of the
purified LN5 was evaluated by silver staining of sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) gels (Fig 1A) and immunoblot analysis (Fig 1B). By
western blot, specific bands of processed LN5 were de-
tected at 165, 140, 155–105 kDa corresponding to the LN
a3, b3, and g2 chains. Thus, affinity purification led to sub-
stantial amounts of intact and fully immunoreactive LN5.
Detection of LN5-specific IgG in MMP and BP sera by
ELISA Sera from patients with MMP (n¼ 24), BP (n¼72),
and from age-matched controls (n¼51) were tested by
ELISA against native LN5, recombinant BP180, BP230, and
fibronectin (FN). Based on the maximization of the Youden
index, the cut-off point for the ELISA with LN5 protein was
set at 0.219 optical density (OD) units for the MMP sera,
which corresponds to a Youden index of 0.563 (Fig 2A).
Reactivity to LN5 was considered positive when the OD of
the BP sera exceeded 0.230 units (Youden index of 0.285)
(Fig 2B).
The diagnostic performance of each test was illustrated
by receiver operating characteristic (ROC) curves (Fig 2A
and B). Using the selected cut-off values, the sensitivity of
the LN5 assay with the MMP sera was 75.0% (95% con-
fidence interval (CI): 53.3%–90.2%) and the specificity was
Figure1
(A, B) Affinity-purified laminin 5 (LN5). (A) Silver stained sodium do-
decyl sulfate-polyacrylamide gel electrophoresis gels run under reduc-
ing conditions of LN5 from SCC-25 cell culture media, before and after
affinity purification from culture supernatants. (B) Mouse anti-LN a3,
goat anti-LN b3, and mouse anti-LN g2, all showed reactivity with the
purified LN5 preparation. The bands shown represent the normal un-
processed and processed forms of the LN5 chains. a3 chain, proc-
essed at 165 kDa; b3 chain, unprocessed at 140 kDa; and g2 chain,
unprocessed at 155 kDa and processed at 105 kDa. The content of
residual fibronectin (FN) in the LN5 preparation was visualized by a goat
anti-FN ab. Numbers on the left of the gels indicate migration positions
of molecular weight marker.
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84.3% (95% CI: 71.4%–93.0%), whereas in the BP sera, the
sensitivity was 40.3% (95% CI: 28.9%–52.5%) and the
specificity was 88.2% (95% CI: 76.1%–95.6%). The diag-
nostic odds ratio was 16.1 (95% CI: 4.9–53.2) in case of
MMP and 5.1 (95% CI: 1.9–13.4) for BP (Table I).
Based on this diagnostic classification, 18/24 (75.0%,
95% CI: 53.3%–90.2%) MMP and 29/72 (40.3%, 95% CI:
28.9–52.5) BP sera were LN5 reactive (Fig 2C). Statistically
significant differences in anti-LN5 IgG reactivity were ob-
served between MMP, BP, and control sera (Kruskal–Wallis
test: po0.0001, 95% CI: 0–0.0005). In pairwise post hoc
Wilcoxon’s tests, the difference between OD values of MMP
or BP patients and controls was highly significant. Further-
more, the difference between MMP and BP OD values
(p¼0.027, 99% CI: 0.023–0.032) was significant. Address-
ing the dichotomized outcome, IgG reactivity against LN5
was significantly more often found in MMP sera than in BP
sera (Fisher’s exact test, two sided: p¼0.0044) (Fig 2C).
In order to exclude background reactivity to FN, the ma-
jor contaminant of the native LN5 preparation, we tested
each serum sample against FN by ELISA and dot blot anal-
ysis. We found a low, negligible reactivity of the tested MMP
and BP sera against FN (data not shown). Comparison
of the LN5 and FN OD values by ELISA revealed only weak
to moderate, albeit significant correlation between LN5
and FN activity (Spearman’s correlation coefficient 0.453,
po0.0001). Similar results were also shown by dot blot
assay.
Detection of LN5-reactive IgG by ELISA and dot blot
analysis A total of 14/24 MMP (58.3%) and 16/72 BP
(22.2%) sera yielded positive results in the dot blot assay
with LN5 (Fig 3A and B). Of the 14 LN5-responsive MMP
patients, five (35.7%) suffered from extensive, five (35.7%)
from limited skin lesions, and four (28.6%) from exclusive
mucosal involvement. Overall, mucosal involvement was
seen in 13 (92.9%) MMP patients. Among the 16 LN5-re-
active BP patients, 13 (87.3%) had extensive, three (18.8%)
limited skin lesions, and three (18.8%) only showed muco-
sal involvement. The details of the clinical phenotype of the
MMP and BP patients are shown in Fig 3B. Both LN5-re-
active MMP and BP sera were more frequently positive by
LN5 dot blot analysis than the LN5-negative sera (Table II).
Specifically, 11/18 MMP (61.1%) and 11/29 BP (37.9%) sera
that were LN5 reactive by ELISA were also positive by dot
blot assay. In general, the diagnostic power of the LN5
ELISA was clearly beyond that of the LN5 dot blot assay
even though there were 3/24 (12.5%) MMP and 5/72
(6.94%) BP sera that were found to be LN5 reactive by dot
blot but not by ELISA (Table II). When FN was used as
Figure 2
(A–C) Sensitivity and specificity of the laminin 5 (LN5) ELISA. The
diagnostic properties of the LN5 ELISA are depicted as receiver op-
erating characteristic curves for (A) mucous membrane pemphigoid
(MMP) and (B) bullous pemphigoid (BP) sera. Sera of patients with
active MMP (n¼24), BP (n¼ 72), and controls (n¼ 51) were screened
for LN5 IgG reactivity by ELISA. (C) Comparing the IgG reactivity
against LN5 in the MMP, BP, and control sera, a significant difference in
the LN5 IgG autoantibody status was found between all three groups in
pairwise tests.
Table I. Sensitivity and speciﬁcity of the laminin 5 (LN5) ELISA
MMP (n¼24) BP (n¼72)
Cutpoint 40.219 40.230
LN5 positive (n) 18 29
Sensitivity
(exact 95% CI)
75.0%
(53.3–90.2)
40.3% (28.9–52.5)
Specifity
(exact 95% CI)
84.3%
(71.4–93.0)
88.2% (76.1–95.6)
Youden index 0.593 0.285
Diagnostic odds
ratioa (95% CI)
16.1
(4.9–53.2)
5.1 (1.9–13.4)
Positive predictive
value (exact 95% CI)
18/26 69.2%
(48.2–85.7)
29/35 82.9% (66.4–93.4)
Negative predictive
value (exact 95% CI)
43/50 87.8%
(75.2–95.4)
45/88 51.1% (40.3–62.0)
MMP, mucous membrane pemphigoid, BP, bullous pemphigoid; CI,
confidence interval.
a(true positives/false negatives)/(false positives/true negatives).
Figure3
(A, B) Anti-laminin 5 (LN5) reactivity of the mucous membrane pe-
mphigoid (MMP) and bullous pemphigoid (BP) sera by dot blot
analysis. (A) A total of 24 MMP, 72 BP, and 51 control sera were
analyzed for LN5 IgG reactivity by dot blot. 14/24 (58.3%) MMP and 16/
72 (22.2%) BP sera reacted with LN5 by dot blot analysis. Represent-
ative dots of the LN5-reactive patients’ and control sera are shown.
Fibronectin (FN) was used as a control protein. (B) The clinical phe-
notype of the LN5-reactive MMP and BP patients is depicted.
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a control antigen in the LN5 ELISA and dot blot analyses,
the MMP, BP, and control sera showed only marginal IgG
reactivity (not shown) (Fig 4).
LN5-specific IgG reactivity and correlation with clinical
severity of MMP and BP Among the patients studied, 10/
24 (41.7%) MMP and 20/72 (27.8%) BP patients presented
with a limited skin involvement, whereas 8/24 (33.3%) MMP
and 50/72 (69.4%) BP patients showed extensive skin le-
sions. The remaining MMP (n¼ 1) and two BP patients
(n¼2) were in remission (Table III). Sera from MMP patients
with extensive skin involvement showed higher average
LN5-specific IgG auto-ab levels by ELISA (p¼0.044, 99%
CI: 0.039–0.05 (Kruskal–Wallis test for overall homogeneity))
than patients with limited disease (Fig 5A). Pairwise post hoc
statistical testing revealed that the difference between lim-
ited and extensive skin involvement in the MMP patients
was significant (p¼ 0.021, 99% CI: 0.017–0.025). In con-
trast, in the BP sera, the IgG auto-ab levels against LN5
neither showed an association with disease severity nor
with the extent of mucosal involvement (Fig 5B). Moreover,
there was no significant difference in the titers of anti-LN5
IgG between untreated and treated MMP and BP patients.
The direct impact of immunosuppressive treatment on IgG
auto-ab titers in individual patients needs to be evaluated in
a larger cohort.
IgG levels against LN5 relate to clinical severity in a
patient with MMP To further substantiate the findings with
the MMP sera, a patient with extensive MMP was subjected
to horizontal serological analysis (Fig 6). This patient initially
presented with bullous and erosive lesions of the oral mu-
cosa, conjunctivae, and extensive skin involvement with
tense blisters that healed with milia formation and atrophy
on the trunk, capillitium, conjuctivae, oral, and genital mu-
cosa (Fig 6A). Serum samples taken over a period of 120 wk
were tested for LN5-specific IgG by ELISA (Fig 6B) and by
dot blot analysis (Fig 6C). LN5-specific IgG titers were
maximal when extensive skin and mucous membrane in-
volvement was present and slowly declined upon clinical
improvement after administration of immunsuppressive
treatment with high-dose methylprednisolone, intravenous
immunoglobulins, and mycophenolate mofetil. Thus, the
levels of circulating LN5-specific IgG auto-ab seemed to
relate to the extent of the overall clinical disease activity in
this case of extensive MMP. A strict direct correlation
between the extent of cutaneous and/or mucosal lesions,
however, was hard to establish. It is noteworthy that ELISA
values and findings of dot blot analysis correlated well
(Fig 6).
The presence of LN5-specific IgG does not relate to IgG
reactivity for BP180 or BP230 IgG reactivity against LN5
of the MMP and BP sera was also compared with anti-
BP180 and anti-BP230 IgG reactivity. A total of 6/24 (25.0%)
MMP and 55/72 (76.4%) BP sera showed IgG reactivity
against BP180, whereas IgG reactivity against BP230 was
observed only in 2/24 (8.3%) MMP and 34/72 (47.2%) BP
sera. It is noteworthy that 4/24 (16.7%) MMP and 8/72
(11.1%) BP sera did not show reactivity either to BP180
and/or BP230 (Table IV).
Among the 18 LN5-reactive MMP sera, four (22.2%)
showed IgG reactivity for BP180 and two (11.1%) for
BP230. Of the 29 LN5-reactive BP sera, 22 (75.9%) showed
IgG reactivity to BP180 and 12 (41.4%) to BP230. In con-
trast, only 22/55 (40.0%) of the BP180-reactive BP sera also
showed IgG reactivity to LN5.
Taken together, there was no significant association be-
tween LN5-specific IgG and IgG reactivity for BP180 or
BP230 both in the MMP and BP sera (Fig 7A and B). Re-
markably, the sera from two MMP patients with extensive
Table II. Diagnostic power of ELISA and dot blot assay in the
detection of IgG reactive with laminin 5 (LN5) in mucous
membrane pemphigoid (MMP) and bullous pemphigoid (BP)
sera
LN5 dot
blot
LN5 ELISA
Positive Negative Total
MMP sera
(n¼24)
Positive 11 (45.0%) 3 (12.5%) 14 (58.3%)
Negative 7 (29.0%) 3 (12.5%)
BP sera
(n¼72)
Positive 11 (15.3%) 6 (8.3%) 16 (22.2%)
Negative 18 (25.0%) 38 (52.7%)
Figure 4
Immunoserological profile of mucous membrane pemphigoid
(MMP) and bullous pemphigoid (BP) patients. The IgG reactivity
pattern of MMP and BP sera with saline-split human skin (SSS) com-
pared with IgG reactivity to laminin 5 (LN5) by ELISA and dot blot
analysis are shown. A significant portion of the 13 SSS-negative MMP
sera and eight SSS-negative BP sera were reactive for LN5 by ELISA or
dot blot analysis.
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mucous membrane involvement, who showed a strong IgG
response to LN5 by ELISA and dot blot analysis, were also
reactive to BP230 (not shown).
Discussion
This study was designed to assess the auto-ab reactivity of
MMP sera against LN5 by a novel ELISA. Our data dem-
onstrate that the majority (75%) of the MMP sera contained
LN5-specific IgG. These findings support the concept that
LN5 is a major auto-ag of MMP. The LN5-negative MMP
sera were presumably reactive to other components of the
BMZ as shown for some of the sera that were BP180 re-
sponsive. It is noteworthy that 40.3% of the sera from pa-
tients with BP, a related autoimmune bullous disorder, also
exhibited titers for LN5-specific IgG above the diagnostic
threshold chosen. Moreover, the titers of anti-LN5 IgG were
found to reflect disease severity in the MMP patients, but
not in patients with BP. The detection of LN5-specific IgG
was relatively specific since control sera from patients with
unrelated skin conditions were only exceptionally reactive.
In this study, dot blot analysis was used as a complemen-
tary assay to confirm the results obtained by ELISA. This
method presented lower sensitivity but better specificity
with regard to making diagnosis in MMP compared with the
ELISA (Table III).
The ELISA protocol presented in this report provides a
convenient and sensitive means by which LN5-specific IgG
auto-ab can not only be detected but also quantified. These
findings strongly suggest (i) that the LN5 ELISA is highly
sensitive and specific for MMP, (ii) that the ELISA also has a
prognostic value in MMP, and (iii) that auto-ab against LN5
are not restricted to MMP, but are also present in BP.
Previous reports on LN5-specific auto-ab in autoimmune
blistering diseases of the pemphigoid group were based on
immunoblot and immunoprecipitation analyses utilizing ep-
idermal extracts (Kirtschig et al, 1995; Ghohestani et al,
1997; Hsu et al, 1997; Nousari et al, 1999). In these studies,
native LN5 was isolated from the extracellular matrix of
cultured human keratinocytes for immunoblotting and/or
immunoprecipitation of MMP serum samples and controls.
There was variability in the data obtained with immunopre-
cipitation experiments ranging from values of 37% to 100%
of MMP patients having a titer for LN5 (Domloge-Hultsch
et al, 1992; Kirtschig et al, 1995; Shimizu et al, 1995; Hashi-
moto et al, 1996; Lazarova and Yancey, 1996; Chan et al,
1997), whereas in the case of immunoblotting experiments
Table III. Clinical phenotype of studied mucous membrane pemphigoid (MMP) and bullous pemphigoid (BP) patientsa
Clinical involvement
Skin
extensiveb Skin limitedc
Mucosal
involvement Oral Genital Conjunctival Capillitium Atrophy Milia
MMP, n¼24 8 (33.3%) 10 (41.7%) 20 (83.3%) 16 (66.7%) 4 (16.7%) 9 (37.5%) 6 (25%) 10 (41.7%) 1 (4.2%)
BP, n¼72 50 (69.4%) 20 (27.8%) 11 (15.3%) 9 (12.5%) 2 (2.7%) 1 (1.4%) 2 (2.7%) 0 0
aOne MMP and two BP patients were in remission.
bExtensive disease, involvement of 415% of total body surface.
cLimited disease, involvement of o15% of total body surface.
Figure 5
(A, B) IgG titers against laminin 5 (LN5) correlate with the clinical
severity of mucous membrane pemphigoid (MMP) but not of bull-
ous pemphigoid (BP). (A) MMP patients with extensive skin involve-
ment had higher LN5-specific IgG autoantibody levels than MMP
patients with limited or exclusive mucous membrane involvement. (B) In
contrast, anti-LN5 IgG reactivity of the BP sera did not show such a
relationship with the clinical status (ns, not significant).
Figure6
(A–C) Anti-laminin 5 (LN5) IgG titers correlate with disease activity
in a patient with mucous membrane pemphigoid (MMP). The clinical
phenotype of a MMP patient (A) over a course of 120 wk and corre-
sponding serum IgG reactivity to LN5 by ELISA (B) and by dot blot
analysis (C) are shown. Remarkably, upon clinical remission the titers of
LN5-reactive IgG declined to threshold levels.
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between 26% and 83% of the MMP sera were found to
have an LN5 IgG titer (Ghohestani et al, 1996a; Kirtschig,
1998; Nousari et al, 1999; Schmidt et al, 2001; Hisamatsu
et al, 2003).
Immunoprecipitation seems to outperform immunoblot
with regard to sensitivity (Hisamatsu et al, 2003). Possible
explanations include differences in selection and number of
the sera investigated as well as varying sensitivities and
specificities depending on the detecting system applied.
Furthermore, by immunoprecipitation native LN5 is detect-
ed, whereas by immunoblot denatured LN5 is recognized
by the sera. Thus, it must be considered that the sensitivity
of the immunoblot may be influenced by loss of immuno-
reactivity of antigenic epitopes because of partial denatur-
ation of LN5 by SDS gel electrophoresis. A previous study
suggested that IgG reactivity against LN5 was detected
both under reducing and non-reducing conditions (Chan
et al, 1997).
A considerable portion of the LN5-responsive MMP and
BP sera were negative by IIF with human SSS as a subst-
rate. This finding is not novel in light of previous studies that
showed that BP and MMP sera that were negative by IIF
were at times reactive with dermoepidermal basement
membrane proteins by immunoblot analysis (Ghohestani
et al, 1996a, 1997). In this study, 4/8 IIF-negative BP sera
showed only low titered IgG auto-ab against LN5 by ELISA,
which may explain the differential reactivity. In contrast, 11
IIF-negative MMP sera that were LN5 responsive by ELISA
had higher auto-ab titers than the BP sera. The lower sen-
sitivity of IIF may be explained by a lower concentration of
antigenic epitopes of LN5 on the substrate that may be
more susceptible to proteolytic degradation. Purified LN5
utilized in a ‘‘native’’ form by ELISA was also superior to the
identical denatured LN5 of immunoblot analysis. Thus, to
definitively rule out the clinical suspicion of MMP, the
present ELISA should be used as an additional diagnostic
tool.
Several cellular sources, including normal human kera-
tinocytes (Hsu et al, 1997), the rat cell line 804G (Baker et al,
1996), the human MCF-10A cell line (Stahl et al, 1997), the
human SCC-25 cell line (Rousselle and Aumailley, 1994),
and the SCC-12 human cell line (Plopper et al, 1996), were
utilized as LN5 sources in the past. An LN5 ELISA with
extracts from cultured human keratinocytes was used to
determine the IgG subclass distribution in selected LN5-
reactive sera (Hsu et al, 1997). It is noteworthy that in this
study, the majority of the MMP sera was negative by IIF, but
LN5 responsive by immunoprecipitation. In addition, an LN5
ELISA using 804G cell-conditioned medium was used for
cell matrix investigations (Plopper et al, 1996). Moreover, an
LN5 ELISA was introduced for the quantification and char-
acterization of LN5 synthesized by human keratinocytes
(Amano et al, 1999).
Since LN5 is presumably a natural ligand of BP180, LN5-
specific auto-ab may contribute to the pathogenesis of
MMP by interfering with LN5–BP180 interaction resulting in
loss of dermo-epidermal adhesion (Borradori and Sonnenb-
erg, 1999; Nievers et al, 2000). This is in line with a previous
report that auto-ab against the COOH terminus of BP180
contribute to the scarring phenotype observed in MMP pa-
tients (Balding et al, 1996). In this study, IgG reactivity
against the COOH terminus of BP180 was detected in 61%
of 23 MMP sera. The COOH-terminal region of BP180 has
been identified as a major epitope recognized by MMP sera
(Balding et al, 1996; Bedane et al, 1997; Nakatani et al,
1998). In two independent studies, the majority (16/19) of
the MMP sera preferentially recognized the NH2-terminal
NC16A region of the BP180 ectodomain (Schmidt et al,
2001), whereas in the second 7/10 (70%) MMP sera reacted
with the NC16A domain of BP180 (Kromminga et al, 2002).
Thus, MMP sera may react with one or both of these an-
tigenic sites of BP180 (Balding et al, 1996). The coincidence
of anti-LN5 and anti-BP180 (NC16A) IgG reactivity has also
been reported by Kawahara et al (1998). In this study, 25%
Table IV. Autoantibody proﬁle of mucous membrane pe-
mphigoid (MMP) and bullous (BP) pemphigoid sera by ELISA
with native laminin 5 (LN5) and recombinant BP180 and BP230
LN5a BP180b BP230c
MMP sera
(n¼ 24)
BP sera
(n¼72)
þ 18 (75.0%) 29 (40.3%)
þ 6 (25.0%) 55 (76.4%)
þ 2 (8.3%) 34 (47.2%)
þ þ 1 (4.2%) 30 (41.7%)
þ þ 4 (16.7%) 22 (30.6%)
þ þ 2 (8.3%) 12 (16.7%)
þ þ þ 1 (4.2%) 12 (16.7%)
 6 (25.0%) 43 (59.7%)
 þ 2 (8.3%) 33 (45.9%)
 þ 0 (0%) 22 (30.6%)
 þ þ 0 (0%) 19 (26.4%)
   4d (16.7%) 8 (11.1%)
aLN5 purified from SCC-25 cell culture supernatant.
bBP180, entire extracellular domain of BP180 (baculovirus derived).
cBP230, NH2, and COOH terminus of BP230 (baculovirus derived).
dThese four MMP sera were also unresponsive to collagen VII.
Gray bars; autoantigen was not taken into consideration.
, not reactive; þ , reactive to above antigen.
Figure 7
(A, B) Relationship of IgG reactivity for laminin 5 (LN5) and bullous
pemphigoid (BP)180 or BP230 of mucous membrane (MMP) and BP
sera. A total of 6/24 (25.0%) of the MMP sera were reactive to BP180,
four of which (16.7%) showed IgG reactivity to LN5 (A). Among the BP
sera, 55/72 (76.4%) were positive for BP180 and 34/72 (47.2%) for
BP230. A total of 22/72 (30.6%) of the BP180-reactive BP sera were
also LN5 reactive and 12/72 (16.7%) of the BP230-positive BP sera
showed IgG reactivity to LN5 (B) (ns, not significant).
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of the MMP and BP sera showed dual IgG reactivity against
BP180 and LN5 but there was no direct correlation to IgG
reactivity against LN5. None of the investigated BP patients
experienced scarring formation of either skin or mucous
membranes, which is in line with a previous ELISA study
(Nakatani et al, 1998). According to a recent study by our
group, 9/16 (52%) BP patients with extensive mucous
membrane involvement showed a dual IgG response
against the NH2- and COOH-terminal domains of BP180
(Hofmann et al, 2002).
In conclusion, the present ELISA with native LN5 is sen-
sitive and specific in detecting LN5-reactive IgG not only in
MMP but also in a subgroup of patients with BP. These
findings suggest that LN5 is a major autoantigen of MMP.
This novel ELISA assay holds great promise as a powerful
diagnostic and prognostic tool in MMP and may eventually
help to clarify the role that ab against LN5 play in the path-
ogenensis of MMP.
Materials and Methods
Patients and controls In this study, we investigated the sera of 24
MMP and 72 BP patients and 51 control donors. The clinical di-
agnosis of MMP with subepidermal blisters and/or signs of pre-
dominating mucous membrane involvement with dermal scarring
was confirmed by direct IF (DIF) with IgG and/or C3 deposits at the
dermal–epidermal BMZ of perilesional skin and/or circulating IgG
binding to the dermal or epidermal side of 1M SSS by IIF micros-
copy. The diagnosis of BP was based on tense blisters on normal
or erythematous skin, IgG and /or C3 deposits at the dermal–ep-
idermal junction in perilesional skin by DIF, and/or circulating IgG
binding to the epidermal side of SSS by IIF. All MMP patients suf-
fered from mucosal lesions at one or more sites at the onset of the
disease or at later stages (e.g., conjunctivae, oral, and genitoanal
region). In contrast, mucosal involvement was only seen in 11/72
(15.3%) BP patients (Table I).
Disease severity of MMP and BP patients was scored accord-
ing to the total skin area afflicted: (1) Limited disease was defined
as the presence of few bullae distributed on a maximum of 15% of
total body surface, (2) extensive disease was associated with bull-
ae that involved a total skin area greater than 15%, and (3) patients
in remission had experienced neither skin nor mucosal lesions for
more than 1 mo. Several patients were on immunosuppressive
treatment.
Control sera were also obtained from patients with pemphigus
vulgaris (PV) (n¼ 9), pemphigus foliaceus (n¼ 3), and individuals
(n¼ 39) who suffered from unrelated acute skin conditions such as
herpes zoster, erysipelas, atopic dermatitis, or acute allergic con-
ditions. The study was conducted according to the declaration of
Helsinki principles. All patients and control donors gave informed
written consent to participate in this study. Patients’ and control
sera were stored at 201C prior to analysis. One serum from a
patient with PV and two sera from unhealthy control individuals,
which were available in large amounts, were used as negative ref-
erence sera for the LN5 IgG ELISA throughout the study.
Production and puriﬁcation of LN5 The squamous carcinoma
cell line SCC-25 (a generous gift from P. Rousselle) was cultured in
50% Ham’s F-12 medium and 50% Dulbecco’s-modified Eagle’s
medium (Gibco-Invitrogen, Karlsruhe, Germany) supplemented
with 10% FCS (PAA, Co¨lbe, Germany), 2 mM glutamine (Sigma,
Taufkirchen, Germany), hydrocortisone (0.4 mg per mL), and pen-
icillin/streptomycin (Sigma) at 371C in a humidified environment at
5% CO2. Cells were harvested by washing subconfluent cultures
with PBS, and with 5 mM EDTA/PBS, followed by incubation
with trypsin/EDTA (Sigma) for 3–4 min at 371C. Cells were, sub-
sequently, resuspended in culture medium containing 10% FCS to
neutralize trypsin, centrifuged at 1200 rpm (241 g) and resuspend-
ed in fresh culture medium. Cell cultures were subcultured every
second day to maintain optimal culture conditions.
For LN5 purification, conditioned media from 80% subconfluent
cultures of SCC-25 cells were collected, centrifuged (to remove
cell debris), sterile filtered, and stored at 41C after addition of pro-
tease inhibitors (5 mM EDTA, 50 mM phenylmethylsulfonylfluoride
and 50 mM N-ethylmaleimide; all from Sigma).
LN5 was purified by affinity chromatography from conditioned
medium as follows: first, FN was removed by chromatography over
gelatin sepharose (20 mL bed volume; Amersham, Freiburg, Ger-
many), which was equilibrated in 50 mM Tris-HCl at pH 8. Sub-
sequently, LN5 was purified by passage over BM165 sepharose
(monoclonal anti-LN5 ab BM165, provided by P. Rousselle) (Rous-
selle et al, 1991). LN5 was eluted from BM165 sepharose using
0.1 M triethylamine. The fractions containing LN5 were pooled,
neutralized by adding 1 M Tris-HCl, pH 8, finally dialyzed against
PBS, and stored at 41C. The eluted protein fraction revealed the
200–165, 140, 155–105–80 kDa bands corresponding to the un-
processed and processed forms of the a3, b3, and g2 chains of
LN5 as shown in Fig 1(Rousselle et al, 1991; Jones et al, 1998;
Goldfinger et al, 1998). Protein concentrations were determined
according to a modified protocol by bicinchoninic acid assay
(Pierce, Bonn, Germany).
Gel electrophoresis and immunoblot analysis of LN5 LN5 was
separated by a SDS-PAGE under reducing conditions (Laemmli,
1970) and was visualized either by silver-stain (Bio-Rad, Munich,
Germany) or transferred onto nitrocellulose (Bio-Rad) for immuno-
blot analysis according to standard procedures (Hofmann et al,
2002). Protein samples were diluted in 5  sample buffer con-
taining 10% SDS, 50% glycine, 10% 2-b-mercaptoethanol, and
0.1% bromophenol blue, denatured for 3 min at 1001C, and sep-
arated by SDS-PAGE on 5% polyacrylamide gels. Separated pro-
teins were transferred onto nitrocellulose (Bio-Rad) using a
transblot system (Biometra, Go¨ttingen, Germany). The membranes
were cut into strips and blocked with milk buffer (5% non-fat dried
milk in Tris-buffered saline (TBS)/0.15% Tween 20) for 1 h. Ab used
included mouse-anti-LNa3 at 1:1000 (BM165, kindly provided by
P. Rousselle), goat-anti-LNb3 at 1:500 (Santa Cruz, Heidelberg,
Germany), mouse-anti-LNg2 at 1:1000 (Chemicon, Hofheim, Ger-
many), and goat-anti-FN at 1:500 (Serotec, Du¨sseldorf, Germany).
All ab were diluted in milk buffer and incubates were performed
overnight at 41C. Ab coupled to horseradish peroxidase (HRP)
were diluted at 1:10000 in milk buffer and added for 1 h at room
temperature (RT). Immunoblots were washed 5  in TBS and
bound ab were visualized with anti-mouse (Dako, Hamburg, Ger-
many), or anti-goat (Amersham) IgG diluted in TBS/0.15% Tween
20, and finally developed using ECL (Amersham).
LN5 ELISA Optimal conditions for the ELISA were established by
testing various sera titrations following published guidelines
(Kemeny, 1991). Microtiter 96-well plates (Maxisorb Immunoplate;
Nunc, Wiesbaden, Germany) were coated overnight at 41C with
1.5 mg LN5 per well. Wells were blocked with milk buffer for 30 min
at RT. All sera were diluted at 1:50 and incubated for 1 h at RT with
the LN5-coated ELISA plates. After three washes with milk buffer,
the plates were incubated with HRP-conjugated anti-human IgG
(Dako) for 1 h at RT. After washing, ab binding was visualized by
adding acino-bis-3-ethylbenzo-thiazoline-6-sulfonic acid (CalBioc-
hem, Bad Soden, Germany) for 30 min at RT. The substrate re-
action was measured at 405 nm by a Wallac 1420 microplate
reader (Wallac, Freiburg, Germany). The cut-off values of the ELISA
for the MMP sera (0.219 OD units) and for the BP sera (0.23 OD
units) were calculated data adaptively based on ROC curves
(Fig 2A and B).
To evaluate potential plate-to-plate variability, each plate in-
cluded a positive control serum from a patient with extensive
MMP and three sera from unhealthy control donors as negative
controls. The values for the positive and negative controls did not
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vary more than 10% when assays performed on different days
were compared.
Since FN represented the major contaminant of the LN5 prep-
aration, all MMP, BP, and control sera were routinely tested against
native FN. FN (1 mg per well) was immobilized onto ELISA plates
and was reacted with the tested sera by ELISA in the same manner
as LN5.
LN5 dot blot analysis LN5 and FN (each at 2 mg per mL diluted in
PBS) were immobilized onto nitrocellulose membranes using a dot
blot chamber (Minifold, Schleicher & Schuell, Dassel, Germany).
The membranes were blocked with milk buffer and were incubated
overnight at 41C with sera diluted at 1:200 in milk buffer. After four
washes with TBS/0.15% Tween 20, the nitrocellulose membranes
were incubated with anti-human IgG (Dako) for 1 h at RT. After
repeated washes (4  with TBS/0.15% Tween 20 and TBS), they
were reacted with ECL (Amersham). Signal intensity was measured
by LAS 1000 (Fuji Film, Du¨sseldorf, Germany). Reading of the
tested sera was evaluated in comparison with the negative controls
and the background reactivity to FN.
BP180 and BP230 ELISA All patients’ sera were screened for the
presence of IgG against BP180 and BP230, to verify the clinical
diagnoses of MMP and BP, respectively. A more detailed descrip-
tion of the ELISA assays and statistical analyses used has been
recently published (Hofmann et al, 2002; Thoma-Uszynski et al,
2004). In this study, we utilized an ELISA with a baculovirus-derived
recombinant form of the BP180 ectodomain and two NH2- and
COOH-terminal recombinants of BP230 (Thoma-Uszynski et al,
2004).
Statistical analysis Statistical analysis was performed using the
statistical software package SAS, version 8.2 (SAS Institute, Cary,
North Carolina). ROC curves were compiled to evaluate the diag-
nostic properties of the LN5 ELISA with respect to correctly clas-
sified cases of BP and MMP (Witte, 2002). As there are no ‘‘natural’’
cutpoints for these ab levels, and as there are no previous studies
that could have contributed evidence concerning an appropriate
diagnostic threshold, an ‘‘optimum’’ cutpoint for the LN5 ELISA
measurement values was determined data adaptively by choosing
the OD values with the largest Youden index (YI¼ sensitivi-
tyþ specificity–1). In detail: sequentially, each measurement ob-
served in the group of patients (cases of BP and MMP,
respectively) and controls, from the lowest to the highest value,
was analyzed as a potential cutpoint. For each provisional cut-
point, the proportion of cases with values above that value that is
correctly classified as BP of MMP, i.e. sensitivity, and the propor-
tion of controls with values below that cutpoint that are correctly
classified as healthy, i.e., specificity, is determined. Hence, the
number of potential cutpoints corresponds to the number of case
þ controls, with increasing specificity and decreasing sensitivity
accompanying increasing measurement values. From this list, the
measurement with the maximum YI is chosen as a definite cut-
point. Several standard measures of diagnostic performance and a
newly suggested summary measure, the ‘‘diagnostic odds ratio’’
(Glas et al, 2003), were calculated based on the cut-off point de-
termined in the ROC analysis.
In view of the skewed distribution of OD values in BP and MMP
patients, which was not amenable to transformation, OD values
were analyzed with non-parametric statistical methods, e.g. Spear-
man’ rank correlation coefficient and Wilcoxon–Mann–Whitney or
Kruskal–Wallis test for overall equality of mean scores. The latter
tests were performed using a Monte Carlo estimate of the exact p-
values, supplemented with a 99% CI. In view of the exploratory
role of statistical testing in our analysis, p-values were not adjusted
for multiple testing; values less than 0.05 were considered signif-
icant.
The distribution of data is shown as a ‘‘box plot’’: the box shows
first and thirsd quartile, the median (as line), and the arithmetic
mean (as dot); the whiskers represent values below the first quartile
and above the third quartile within the 1.5-fold inter-quartile range,
respectively, and outliers beyond the whiskers are shown as
squares.
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